コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 with the conjugate vaccine compared with the pneumococcal polysaccharide vaccine.
2 re due to serotypes covered by the 23-valent pneumococcal polysaccharide vaccine.
3 were serotypes represented in the 23-valent pneumococcal polysaccharide vaccine.
4 lysaccharides used to formulate a polyvalent pneumococcal polysaccharide vaccine.
5 ates were serotypes that are included in the pneumococcal polysaccharide vaccine.
6 9F, and 23F linked to CRM197, or a 23-valent pneumococcal polysaccharide vaccine.
7 long-lasting, impaired antibody responses to pneumococcal polysaccharide vaccines.
8 the influence of Km and Gm allotype genes on pneumococcal polysaccharide vaccines.
9 ons manifest decreased antibody responses to pneumococcal polysaccharide vaccines.
11 7; Prevnar) in infancy followed by 23-valent pneumococcal polysaccharide vaccine (23vPPV; Pneumovax)
12 -treated patients had decreased responses to pneumococcal polysaccharide vaccine (57% of patients had
13 uded in the 7-valent conjugate and 23-valent pneumococcal polysaccharide vaccines accounted for 78 pe
14 s, but it remains unclear whether use of the pneumococcal polysaccharide vaccine alters the overall r
16 rgeting high-risk groups was undertaken with pneumococcal polysaccharide vaccine, and subsequently ra
18 Four of 16 patients in group 1 responded to pneumococcal polysaccharide vaccine compared with 14 of
21 se findings support the effectiveness of the pneumococcal polysaccharide vaccine for the prevention o
24 gate vaccine followed by 1 dose of 23-valent pneumococcal polysaccharide vaccine or a single dose of
25 rted that the 7-valent diphtheria-conjugated pneumococcal polysaccharide vaccine (PCV7) is safe and i
26 administration of the heptavalent conjugated pneumococcal polysaccharide vaccine (PCV7) were also ass
29 ther passive immunization with the 23-valent pneumococcal polysaccharide vaccine (Pneumovax(R) 23; PP
31 udy murine immune responses to the 23-valent pneumococcal polysaccharide vaccine Pnu-Imune, both in v
33 dose 6 months later, and 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) 1 month lat
34 gate vaccine (PCV13) compared with 23-valent pneumococcal polysaccharide vaccine (PPSV23) among US ad
35 ortions and incidence matching the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-vale
36 usly vaccinated with >/= 1 dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) and had CD4
37 tion Practices has recommended the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for nonelde
38 PD), with the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for prevent
40 Controversy persists over the benefits of pneumococcal polysaccharide vaccine (PPV) for adults at
43 umonia (n = 16) and healthy volunteers given pneumococcal polysaccharide vaccine (PPV; n = 14) or pne
44 determine the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) among Navajo
46 grouped serotypes contained in the 23-valent pneumococcal polysaccharide vaccine (PPV23) decreased at
49 >/= 200 randomized to receive the 23-valent pneumococcal polysaccharide vaccine (PPV23) or placebo a
51 althy human adults with Pneumovax (23-valent pneumococcal polysaccharide vaccine [PPV23]), IgG anti-c
54 rs after transplantation and the response to pneumococcal polysaccharide vaccine was significantly lo
55 sera of people immunized with the 23-valent pneumococcal polysaccharide vaccine, we confirmed that h
56 ne response to that induced by the 23-valent pneumococcal polysaccharide vaccine, which has been the
57 eritoneal B1b compartment, immunization with pneumococcal polysaccharide vaccine yielded comparable a
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。